O'CollinsVEMacleodMRDonnanGAHorkyLLvan der WorpBHHowellsDW. 1,026 experimental treatments in acute stroke. Ann Neurol2006; 59:467–77.
2.
AlbersGWAtkinsonRPKelleyRERosenbaumDM. Safety, tolerability, and pharmacokinetics of the N-menthyl-d-aspartate antagonist dextrorphan in patients with acute stroke. Stroke1995; 26:254–258.
3.
ShuaibALeesKRLydenP. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med2007; 357:562–71.
4.
LydenPDShuaibALeesKR. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: The CHANT Trial. Stroke2007; 38:2262–9.
5.
Haley EC Jr High-dose tirilazad for acute stroke (RANTTAS II).RANTTAS II Investigators. Stroke1998; 29:1256–7.
6.
NINDS rt-PA Stroke Study Group.Tissue plasminogen activator for acute ischemic stroke. N Engl J Med1995; 333:1581–7.
7.
NINDS rt-PA Stroke Study Group.Generalized efficacy of t-PA for acute stroke. Stroke1997; 28:2119–2125.
8.
HemmenTMLydenPD. Multimodal neuroprotective therapy with induced hypothermia after ischemic stroke. Stroke2008; 40(Suppl.): S126–8.
